K. Schmid

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
K Schmid, K. W. Schmid, K. W Schmid, K. w. Schmid, K-w Schmid, Kurt W Schmid, K W Schmid, K.w. Schmid, Kurt Werner Schmid, Kurt‐werner Schmid, K.‐w. Schmid, Kurt-werner Schmid, K. Schmid, Kurt Schmid, Kurt W. Schmid
Publication record
520 papers · 16,343 citations · H-index 65

PAPERS

Multimodal survival prediction in advanced pancreatic cancer using machine learning
202234 citationsauthor #14
Digital gene expression analysis of NSCLC-patients reveals strong immune pressure, resulting in an immune escape under immunotherapy
20220 citationsauthor #10
Identification of a new prognostic score for patients with high-grade metastatic GEP-NEN treated with palliative chemotherapy
20223 citationsauthor #3
CAF-Associated Paracrine Signaling Worsens Outcome and Potentially Contributes to Chemoresistance in Epithelial Ovarian Cancer
202216 citationsauthor #6
Digital gene expression analysis of NSCLC-patients reveals strong immune pressure, resulting in an immune escape under immunotherapy
20225 citationsauthor #10
Enhancing Radioiodine Incorporation into Radioiodine-Refractory Thyroid Cancer with MAPK Inhibition (ERRITI): A Single-Center Prospective Two-Arm Study
202256 citationsauthor #10
Clonidine suppression test for a reliable diagnosis of pheochromocytoma: When to use
202212 citationsauthor #7
Cancer-Associated Fibroblasts Regulate Kinase Activity in Mesothelioma Cell Lines via Paracrine Signaling and Thereby Dictate Cell Faith and Behavior
20224 citationsauthor #10
Molecular Subtyping of Invasive Breast Cancer Using a PAM50-Based Multigene Expression Test-Comparison with Molecular-Like Subtyping by Tumor Grade/Immunohistochemistry and Influence on Oncologist’s Decision on Systemic Therapy in a Real-World Setting
202210 citationsauthor #8
Rebiopsy in advanced non-small cell lung cancer, clinical relevance and prognostic implications.
202212 citationsauthor #20
The prevalence of DNA microsatellite instability in anaplastic thyroid carcinoma – systematic review and discussion of current therapeutic options
202118 citationsauthor #2
Age, ATA risk group and response to therapy are prognostic factors in children with differentiated thyroid cancer.
202116 citationsauthor #6
DLL3 (delta-like protein 3) expression correlates with stromal desmoplasia and lymph node metastases in medullary thyroid carcinomas
202113 citationsauthor #8
Abandoning node dissection for desmoplasia-negative encapsulated unifocal sporadic medullary thyroid cancer.
202122 citationsauthor #6
Optimisation of the Chicken Chorioallantoic Membrane Assay in Uveal Melanoma Research
202123 citationsauthor #4
Analysis of risk factors and prognosis in differentiated thyroid cancer with focus on minimal extrathyroidal extension
20218 citationsauthor #9
Mitogen signal-associated pathways, energy metabolism regulation, and mediation of tumor immunogenicity play essential roles in the cellular response of malignant pleural mesotheliomas to platinum-based treatment: a retrospective study
20212 citationsauthor #12
BRAF mutations and BRAF mutation functional class have no negative impact on the clinical outcome of advanced NSCLC and associate with susceptibility to immunotherapy.
202115 citationsauthor #14
Diagnostische Grundlagen von Schilddrüsentumoren in der Pathologie
20212 citationsauthor #4
Apoptotic Gastritis in Melanoma Patients Treated With PD-1-Based Immune Checkpoint Inhibition – Clinical and Histopathological Findings Including the Diagnostic Value of Anti-Caspase-3 Immunohistochemistry
202113 citationsauthor #9
Streptozocin/5-fluorouracil chemotherapy of pancreatic neuroendocrine tumours in the era of targeted therapy
202115 citationsauthor #9
Digital Gene Expression Analysis of Epithelioid and Sarcomatoid Mesothelioma Reveals Differences in Immunogenicity
20218 citationsauthor #14
Identification of a Prognostic Clinical Score for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated With Systemic Therapy Including Cetuximab
20217 citationsauthor #7
Therapeutic Effect of Combined Dabrafenib and Trametinib Treatment of BRAF V600E-Mutated Primary Squamous Cell Carcinoma of the Thyroid: A Case Report
20215 citationsauthor #4
Electrochemotherapy with Bleomycin Enhances Radiosensitivity of Uveal Melanomas: First In Vitro Results in 3D Cultures of Primary Uveal Melanoma Cell Lines
202113 citationsauthor #5
Management of primary and renal hyperparathyroidism: guidelines from the German Association of Endocrine Surgeons (CAEK)
202137 citationsauthor #27
922P Efficacy of immunotherapy (IO) and subsequent systemic treatment after failure of IO in patients with recurrent or metastatic head and neck cancer in a real-world setting
20211 citationsauthor #9
Pulmonary echinococcosis: A rare pseudotumour of the lung
20215 citationsauthor #6
Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus Trametinib
202113 citationsauthor #20
Continued Discontinuation of TKI Treatment in Medullary Thyroid Carcinoma – Lessons From Individual Cases With Long-Term Follow-Up
20217 citationsauthor #6
Differentiating Benign from Malignant Adrenocortical Tumors by a Single Morphological Parameter—a Clinicopathological Study on 837 Adrenocortical Neoplasias
20206 citationsauthor #6
HDAC Inhibition Induces PD-L1 Expression in a Novel Anaplastic Thyroid Cancer Cell Line
202025 citationsauthor #12
Acute myeloid leukemia-induced remodeling of the human bone marrow niche predicts clinical outcome.
202032 citationsauthor #6
Characterization of two types of intranuclear hepatocellular inclusions in NAFLD
202015 citationsauthor #9
An animal model further uncovers the role of mutant BrafV600E during papillary thyroid cancer development.
20204 citationsauthor #10
CMAR_A_258396 7881..7890
20200 citationsauthor #12
Impact of metallothionein-knockdown on cisplatin resistance in malignant pleural mesothelioma
202022 citationsauthor #14
[Angiomyolipoma of the liver-a case report and review of the literature].
20200 citationsauthor #6
Correction to: The natural course of pT2 prostate cancer with positive surgical margin: predicting biochemical recurrence
20200 citationsauthor #18
β-catenin in intranuclear inclusions of hepatocellular carcinoma
20202 citationsauthor #7
Advances in the Diagnosis and Surgical Management of Medullary Thyroid Carcinomas
20203 citationsauthor #2
A Novel Epitope Quality-Based Immune Escape Mechanism Reveals Patient’s Suitability for Immune Checkpoint Inhibition
20206 citationsauthor #12
Urachal Cancer in Germany and the USA: An RKI/SEER Population-Based Comparison Study
202015 citationsauthor #5
Biweekly Cetuximab Plus FOLFOX6 as First-Line Therapy in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The CEBIFOX Trial.
20207 citationsauthor #18
Immunohistochemical Profile and 47-Gene Next-Generation Sequencing (NGS) Solid Tumor Panel Analysis of a Series of 13 Strumal Carcinoids
202013 citationsauthor #5
Machine learning reveals a PD-L1-independent prediction of response to immunotherapy of non-small cell lung cancer by gene expression context.
202047 citationsauthor #18
Influence of Methallothionein Expression on Sensitivity Against Platin Compounds in Human Malignant Pleural Mesothelioma Cell Lines – Knock-Down of Gene Expression as New Therapeutic Approach?
20190 citationsauthor #14
Papilloma of the Fallopian Tube: A Rare Gynecologic Neoplasm Harboring a BRAF (c.1799T>A) Mutation (V600E)
20191 citationsauthor #7
Setting out the frame conditions for feasible use of FFPE derived RNA.
201913 citationsauthor #7
Increased Anaplastic Lymphoma Kinase Activity Induces a Poorly Differentiated Thyroid Carcinoma in Mice
20198 citationsauthor #12
Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitro
20194 citationsauthor #15
Bortezomib sensitivity is tissue dependent and high expression of the 20S proteasome precludes good response in malignant pleural mesothelioma
201911 citationsauthor #10
Screening of Pleural Mesothelioma Cell Lines for Kinase Activity May Identify New Mechanisms of Therapy Resistance in Patients Receiving Platin-Based Chemotherapy
20196 citationsauthor #12
New insights into intranuclear inclusions in thyroid carcinoma: Association with autophagy and with BRAFV600E mutation
201915 citationsauthor #11
Digital Immune-Related Gene Expression Signatures In High-Grade Serous Ovarian Carcinoma: Developing Prediction Models For Platinum Response
201920 citationsauthor #3
Dissimilar patterns of tumor-infiltrating immune cells at the invasive tumor front and tumor center are associated with response to neoadjuvant chemotherapy in primary breast cancer
201942 citationsauthor #5
Bortezomib sensitivity is tissue dependent and high expression of the 20S proteasome precludes good response in malignant pleural mesothelioma
20190 citationsauthor #10
Targeting claudin‐overexpressing thyroid and lung cancer by modified Clostridium perfringens enterotoxin
201925 citationsauthor #8
Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitro
201929 citationsauthor #15
The mismatch repair system is not affected in medullary thyroid carcinoma independent of stromal desmoplasia or ret proto-oncogene mutation.
20198 citationsauthor #3
Intranuclear inclusions in hepatocellular carcinoma contain autophagy‐associated proteins and correlate with prolonged survival
201911 citationsauthor #10
P1.04-27 Processing Escapes: Novel Resistance Mechanisms Under Immune Checkpoint Inhibition in NSCLC
20190 citationsauthor #13
CMAR_A_219872 9571..9583
20190 citationsauthor #3
The GNAS SNP c.393C>T (rs7121) as a marker for disease progression and survival in cancer.
201913 citationsauthor #2
P1.06-12 Defects in Homologous Recombination Repair Indicates Susceptibility for Olaparib Treatment in Malignant Pleural Mesothelioma
20190 citationsauthor #15
Thyroxine promotes lung cancer growth in an orthotopic mouse model.
201922 citationsauthor #5
Prognostic significance of PD-1 and PD-L1 positive tumor-infiltrating immune cells in ovarian carcinoma
201924 citationsauthor #6
In a Novel Malignant Pleural Effusion Derived Anaplastic Thyroid Cancer Line PD-L1 Expression is Strongly Increased by HDAC Inhibitor Treatment
20190 citationsauthor #7
Immunohistochemically detectable metallothionein expression in malignant pleural mesotheliomas is strongly associated with early failure to platin-based chemotherapy
201811 citationsauthor #15
Inhibition of MDM2 via Nutlin-3A: A Potential Therapeutic Approach for Pleural Mesotheliomas with MDM2-Induced Inactivation of Wild-Type P53
201812 citationsauthor #15
Methylation of L1RE1, RARB, and RASSF1 function as possible biomarkers for the differential diagnosis of lung cancer
201837 citationsauthor #12
[Proposal for an extended pTNM classification of thyroid carcinoma : Commentary on deficits of the 8th edition of the TNM classification (German version)].
201810 citationsauthor #1
MET Expression in Advanced Non–Small‐Cell Lung Cancer: Effect on Clinical Outcomes of Chemotherapy, Targeted Therapy, and Immunotherapy
201869 citationsauthor #20
Development of predictors for PD-1/PD-L1-directed therapy of non-small cell lung cancer (NSCLC) by gene expression profiling of small diagnostic biopsies (DBX).
20180 citationsauthor #14
Inhibition of MDM 2 via Nutlin-3 A : A Potential Therapeutic Approach for Pleural Mesotheliomas with MDM 2-Induced Inactivation of Wild-Type P 53
20181 citationsauthor #15
Rapid and Highly Sensitive Detection of Therapeutically Relevant Oncogenic Driver Mutations in EBUS‐TBNA Specimens From Patients With Lung Adenocarcinoma
201810 citationsauthor #9
Phosphorylation of p70 Ribosomal Protein S6 Kinase &bgr;‐1 is an Independent Prognostic Parameter in Metastatic Colorectal Cancer
201810 citationsauthor #16
Processing Escape Mechanisms Through Altered Proteasomal Cleavage of Epitopes Affect Immune Response in Pulmonary Neuroendocrine Tumors
20185 citationsauthor #14
Pathogenic and targetable genetic alterations in 70 urachal adenocarcinomas
201854 citationsauthor #34
Potentially Targetable Molecular Alterations in 70 Cases of Urachal Cancer
20180 citationsauthor #28
Molecular dissection of effector mechanisms of RAS-mediated resistance to anti-EGFR antibody therapy
201713 citationsauthor #18
Folic acid phenotype (FAP) is a superior biomarker predicting response to pemetrexed-based chemotherapy in malignant pleural mesothelioma
20179 citationsauthor #5
Poster SessionP3.02b-025 Rapid and Highly Sensitive EGFRdelEx19 and KRAS Exon 2 Mutation Detection in EBUS-TBNA Specimen of Lung Adenocarcinoma: Topic: EGFR Biomarkers
20170 citationsauthor #8
miRNA regulation is important for DNA damage repair and recognition in malignant pleural mesothelioma
201728 citationsauthor #12
Abstract 3993: A different spatiotemporal distribution of TIL subtypes is associated with response to neoadjuvant chemotherapy in locally advanced breast cancer patients
20170 citationsauthor #5
Abstract P1-01-09: Comparison of HER2, estrogen and progesterone receptor expression profiles of primary tumor, synchronous axillary lymph node metastases and circulating tumor cells in early breast cancer patients
20170 citationsauthor #7
Curcumin induces G2/M arrest, apoptosis, NF-κB inhibition, and expression of differentiation genes in thyroid carcinoma cells
201757 citationsauthor #5
Cytomegalovirus reactivation in patients with refractory checkpoint inhibitor-induced colitis.
201774 citationsauthor #9
Post-Chernobyl Pediatric Papillary Thyroid Carcinoma in Belarus: Histopathological Features, Treatment Strategy, and Long-Term Outcome
20171 citationsauthor #5
Erratum to: Curcumin induces G2/M arrest, apoptosis, NF-κB inhibition, and expression of differentiation genes in thyroid carcinoma cells
20173 citationsauthor #5
1192PCytomegalovirus reactivation in patients with refractory checkpoint inhibitor-induced colitis
20171 citationsauthor #9
Impact of BCL2 polymorphisms on survival in transitional cell carcinoma of the bladder
20172 citationsauthor #6
Differential regulation of monocarboxylate transporter 8 expression in thyroid cancer and hyperthyroidism.
201721 citationsauthor #8
NGS based identification of mutational hotspots for targeted therapy in anaplastic thyroid carcinoma
201770 citationsauthor #10
High Prevalence of Concomitant Oncogene Mutations in Prospectively Identified Patients with ROS1‐Positive Metastatic Lung Cancer
201767 citationsauthor #21
Max Schottelius: Pioneer in Pheochromocytoma
201718 citationsauthor #3
Prognostic markers and response to vandetanib therapy in sporadic medullary thyroid cancer patients.
201617 citationsauthor #8
microRNAs are differentially regulated between MDM2-positive and negative malignant pleural mesothelioma
201617 citationsauthor #6
Screening of Pleural Mesotheliomas for DNA-damage Repair Players by Digital Gene Expression Analysis Can Enhance Clinical Management of Patients Receiving Platin-Based Chemotherapy
201620 citationsauthor #16
ACTB, CDKN1B, GAPDH, GRB2, RHOA and SDCBP Were Identified as Reference Genes in Neuroendocrine Lung Cancer via the nCounter Technology
201634 citationsauthor #8

TIMELINE

1984 0 citations

1986 189 citations

1987 22 citations

1988 46 citations

1989 218 citations

1990 178 citations

1991 126 citations

1992 242 citations

1993 20 citations

1994 458 citations

1995 531 citations

1996 612 citations

1997 404 citations

1998 429 citations

1999 436 citations

2000 146 citations

2002 523 citations

2003 166 citations

2004 752 citations

2005 642 citations

2006 1,000 citations

2007 1,045 citations

2008 1,609 citations

2009 670 citations

2010 734 citations

2011 809 citations

2012 870 citations

2013 684 citations

2014 509 citations

2015 393 citations

2016 464 citations

2017 364 citations

2018 219 citations

2019 252 citations

2020 197 citations

2021 243 citations

2022 152 citations

Unknown 4 citations

K. Schmid

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT